

# **NTR Face-to-Face Meeting**

**Location: NCI Executive Plaza**

**Thursday and Friday 17-18<sup>th</sup> February 2011**

## **Final Agenda**

### **Thursday**

**7:30 Gathering-Coffee -Light refreshments**

**7:45 NCI Program: Overview of NTR meeting agenda**

Larry Clarke, Ph.D., and Robert Nordstrom, Ph.D.

Imaging Technology Development Branch

Paula Jacobs PhD., Acting AD

Cancer Imaging Program, NCI

**8:00-12:00 Session 1: NTR PI Center Presentations:  
Research Progress Year 2 and Validation Strategies for Years 3-5.  
(40 Minute presentation, 10 min discussion, 10 min break).  
Session Chairs: Robert Nordstrom and Eva Sevick**

Goals are to cover the following:

1. Executive Summary (20) Minutes:
  - a. Overall clinical rationale for the targeted cancer problem
  - b. Primary Project: Proposed Imaging Platform-probes/agents
  - c. Platform validation strategy proposed
  - d. Task specific projects and relationship to primary project
  - e. Project timeline: Translational roadmap slide
  - f. Research Cores: One slide on value of NTR open science validation strategy within context of (FDA/CMS)
  
2. Research Details ( 20 min)
  - a. Imaging methods
  - b. Validation methods
  - c. Translational research barriers
  - d. Scientific progress to date

**8:00 Center #1: Washington University**

Lihong Wang, Ph.D.

**9:00 Center #2: University of Texas Health Science Center**

Eva Sevick, Ph.D.

**10:00**      **Center #3: University of Michigan**  
Thomas Wang, M.D., Ph.D.

**11:00**      **Center #4: Stanford University**  
Christopher Contag, Ph.D.

**12:00**      **Lunch Break**

**1:00-3:00**      **Session 2: NTR Core Presentations.**  
**Session Chairs: Larry Clarke and Chris Contag**  
**20 min presentation, 5 min discussion, 5 min break, total 30 min.**

Goals: Provide a brief outline of the progress to date for the research cores and timelines for deliverables, and describe how they have met or positioned to meet NTR expectations in terms of improvement in translational research timelines. Place a specific emphasis on how the research cores are addressing consensus approaches on validation strategies, and indicate planned consensus based publications. The overriding goal is to demonstrate the value of the research cores to the NTR mission.

**1:00**      **Research Core 1: Standards, Compliance, Validation & Clinical Studies**

**1:30**      **Research Core 2: Information Technology**

**2:00**      **Research Core 3: Instrumentation & Industrial Relations**

**2:30**      **Research Core 4: Chemistry Probes & Guided Therapeutics**

**3:00**      **Break**

**3:15 – 5:00**      **Panel Session: NTR Industry perspective: FDA CMS**  
**Chairs: NCI: Gary Kelloff,-Rueben Mezrich**  
**FDA: Jonathan Sackner-Bernstein (CDRH), Orhan Suleiman (CDER)**  
**Panel Participants: All Representatives: Industry FDA and CMS**

Goal: Evaluate NTR open science validation goals in terms of their potential to help accelerate FDA approval and CMS reimbursement for the next generation of imaging technologies. Identify how these goals can be strengthened as a resource to the broader device and drug industry as a whole; specifically not for a specific product being developed by NTR industry partners.

See recent FDA guidance document for reference to “Qualification Process for Drug Development Tools” as an example of the importance of the organization of consortia of industry and academia:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf>

5:00 Close Day 1

6:00 Informal dinner

---

## Friday

7:30 Gathering-Coffee -Light refreshments

8:00 NTR Research Cores: Breakouts (1.5 hours)

Goal: Discuss plans for consensus building during the next year.

9:45 Coffee Break

10:00 - 11:00 **Session 3: Other NCI Programs and Opportunities**  
Chair: Larry Clarke

10:00 NCI NeXT Program

Goals: To provide an overview of the NCI NeXT program that is developing extensive resources to facilitate IND approval for drug-molecular probes

**Speakers: Barbara Mroczkowski PhD, and Jason Cristofaro PhD, DCTD, NCI**

10.30 **Potential roles of NTR platforms for discovery research and in vivo systems biology.**

Goals: To alert NTR members of new opportunities where the NTR platforms being developed may potentially be employed for both discovery research and in-vivo systems biology. NTR scientists are thus encouraged to seek additional R01 funding for further development of technologies and link to NTR.

**Speaker: Jennifer Couch PhD,  
Division of Cancer Biology, NCI Extramural**

11:00 - 12:00 **Nanotechnology and Early Detection**  
Chair: Pushpa Tandon

Goal: Update on programs of importance to NTR

11:00 **Nanotechnology Alliance**  
Sara Hook, PhD

**11:30**      **Early Cancer Detection**  
Richard Mazurchuk, PhD

**12:00**      **Lunch**

**1:30**      **NTR SC Meeting: Management and Organizational Issues**  
**NTR PI's, Co-PI's, Four Core Chairs/Co chairs, Program Staff**

Agenda to include

1. Future NTR meetings and annual reports
2. Logistics for Core T- Con's and potential alternatives
3. Planned NTR publications
4. Importance of leveraging R01 funding with U54
5. Other PI items

**2:30**      **Close of Meeting**